CTRI/2020/05/025353尚未招募2 期
Adjuvant chemotherapy for operated amPullary AdenoCarcinomas based on Histology and Intensification â?? A two arm non - randomized open label prospective parallel adaptive design phase II clinical trial (APACHI)
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •No radiological evidence of metastatic disease or and metastatic disease as discovered by on-table evaluation during definitive surgery for GBC peritoneal disease, liver metastases etc
- •-Histologically confirmed adenocarcinoma of the ampulla post resection with the following specifications
- •-Anatomical
- •-Growth in the lumen or walls of the distal ends intra-ampullary component) of the common bile duct (CBD) and or pancreatic duct, or
- •- Growth at the papilla of Vater, or
- •-Growth at the duodenal surface of the papilla (the duodenal-facing surface of the ampullary protuberance) with the ampullary orifice clearly located within this lesion.
- •-Stage as per AJCC 8th edition
- •-R0/R1 resection
- •-ECOG performance status 0 - 1
- •-Patient who can give informed consent for the study.
- •-Patient does not have any contraindications to receive chemotherapy.
- •-Duration between surgery and fitness for randomization to adjuvant therapy more than or equal to 90 days.
- •-Adequate hematological, hepatic and renal function parameters· Hematological- Hb more than 80 g/L, ANC more than equal to 1.5 x 109/L, platelets more than equal 100 x 109/L. Liver functions bilirubin less than or equal to 2 x upper limit normal (ULN), AST ALT less than equal to 5 x ULN, S. albumin more than equal to 30 g/L, Renal function Creatinine less than equal to 1.5 ULN, Creatinine clearance more than equal to 50 mL/min.
- •-Normal cardiac function, as assessed by echocardiography and ECG
- •-Women of childbearing age should have a negative pregnancy test at the time of randomization and should be willing to use adequate contraception during the treatment phase of the trial.
- •-Written patient consent form
排除标准
- •-Resected Pancreatic cancers or resected patients with doubtful epicenter of primary
- •-R2 resections.
- •-Known hypersensitivity or contraindications against capecitabine, 5 FU, Irinotecan, or Oxaliplatin.
- •-Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, NYHA III-IV,
- •-Clinically significant valvular defect
- •-Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix
- •-Severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy, NYHA ATS G2 and above
- •-Other severe internal disease or acute infection
- •-Baseline neuropathy more than NCI Grade I
- •-Chronic inflammatory bowel disease
- •-On-treatment participation in another clinical study in the period 30 days prior to inclusion and during the study
- •-Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
研究者
相似试验
尚未招募
2 期
Histology based adjuvant chemotherapy in ampullary cancer a phase II trialCTRI/2023/02/049494AIG Hospitals
已完成
2 期
eoadjuvant chemoradiation for patients with adenocarcinoma of the stomach. A feasibility and efficacy study.1001799010017991gastric cancerNL-OMON33628niversitair Medisch Centrum Groningen25
已完成
2 期
Feasibility study of adjuvant chemotherapy with alternate-day administrations of S-1 in patients with resected pancreatic cancerpancreatic cancerJPRN-UMIN000009936Fukushima Medical University Hospital, School of medicine30
已完成
2 期
Adjuvant chemotherapy for completely rsected non-small cell lung cancer with TS-1 - evaluation of predictive factors for prognosiscompletely resected non-small cell lung cancerJPRN-UMIN000001049Division of General Thoracic Surgery, Keio University, School of Medicine,200
招募中
不适用
Feasibility study of adjuvant chemotherapy with nanoparticle albumin-bound (nab)- paclitaxel and carboplatin in patients with completely resected pathological IB non small cell lung canceron-small cell lung cancerJPRN-UMIN000011215Department of Thoracic Surgery , Faculty of Life Science Kumamoto University35